<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512408</url>
  </required_header>
  <id_info>
    <org_study_id>002-07</org_study_id>
    <nct_id>NCT00512408</nct_id>
  </id_info>
  <brief_title>Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure</brief_title>
  <official_title>Long-Acting Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <brief_summary>
    <textblock>
      Background: Patients with congestive heart failure (CHF) show muscle mass wasting and
      decreased testosterone levels. Long-term testosterone supplementation improves walking
      distance and glucose metabolism of patients CHF. No studies have investigated the integrated
      effects of testosterone on exercise oxygen uptake muscle strength and glucose metabolism in
      patients with CHF regardless of the presence of hypogonadism.

      Aim: To assess the effect of a 12 week testosterone administration on maximal exercise
      capacity, muscle strength and insulin resistance in elderly CHF patients.

      Methods: Seventy elderly patients with stable CHF, mean age 71 ± 8 years, ejection fraction
      34 ± 1%, NYHA class II/III 38/32, were enrolled. Of these, 35 were randomized to receive
      testosterone therapy (through intramuscular injection every 6 week) and 35 to receive placebo
      both on top of maximal medical therapy. At baseline and after 12 weeks all patients underwent
      echocardiogram, cardiopulmonary test, 6-minute walking test (6MWT), quadriceps maximal
      isometric and isokinetic strength.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  left ventricular ejection fraction (LVEF) &lt; 40%;

          -  New York Heart Association (NYHA) class II or III;

          -  clinical stability without hospital admission for heart failure in the previous 3
             months.

        Exclusion Criteria:

          -  unstable angina or recent acute myocardial infarction,

          -  history of severe liver diseases

          -  history of severe kidney diseases

          -  uncontrolled hypertension

          -  erythrocytosis (hematocrit &gt; 50%)

          -  hyperviscosity

          -  prostate cancer, prostate-specific antigen (PSA) greater than 3 ng/ml

          -  severe lower urinary tract symptoms.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>maurizio volterrani, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>giuseppe marazzi, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>massaro rosalba, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>marco miceli</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>caterina mammi</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>massimo fini, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>giuseppe rosano, md</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <keyword>To assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly CHF patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

